News for Novo Nordisk Stock (NVO)

Novo Nordisk Eyes Another Breakout As Weight-Loss Battle Continues

Investors Business Daily • 11/16/23

Better Growth Stock: Novo Nordisk vs. Eli Lilly

The Motley Fool • 11/16/23

Investors increase holdings of weight-loss drug makers' shares in Q3 -filings

Reuters • 11/14/23

Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds

Market Watch • 11/14/23

Wegovy's Sales Potential Could Go Far Beyond Just Weight-Loss Treatment

The Motley Fool • 11/14/23

Belgium bans use of Ozempic for weight loss until summer

Reuters • 11/14/23

Better Growth Stock: Pfizer vs. Novo Nordisk

The Motley Fool • 11/14/23

Jim Cramer says insurance companies will pay for 'revolutionary' weight-loss drugs for their members

CNBC • 11/14/23

Novo Nordisk ADRs Climb After Study Suggests Its Wegovy Showed Heart Benefits

Investopedia • 11/13/23

Novo Nordisk Stock Skids — But These Weight-Loss Results Are 'Hard To Ignore'

Investors Business Daily • 11/13/23

Novo Nordisk's (NVO) Wegovy Positive in Cardiovascular Study

Zacks Investment Research • 11/13/23

4 Large Drug Stocks Likely to Sail Through Industry Woes

Zacks Investment Research • 11/13/23

Wegovy predicted to become huge drug as weight loss benefits confirmed

Proactive Investors • 11/13/23

Novo Nordisk A/S (NVO) Novo Nordisk R&D Investor Event (Transcript)

Seeking Alpha • 11/13/23

The Magnificent Seven: 7 Stocks That Could Make It the ‘Elite Eight'

InvestorPlace • 11/13/23

The Outlook for Weight-Loss Drugs Just Got 'Turbocharged.' Here's Why.

Barrons • 11/13/23

Better Buy Now: Novo Nordisk vs. Eli Lilly

The Motley Fool • 11/13/23

Novo Nordisk shares rise as Wegovy shows heart benefits beyond weight loss

Reuters • 11/13/23

Novo Nordisk's Wegovy cuts risk of heart attack and stroke by 20% among people without diabetes, study finds

Market Watch • 11/11/23

Novo Nordisk says Wegovy heart benefits due to more than weight loss

Reuters • 11/11/23

Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine

GlobeNewsWire • 11/11/23

Novo Nordisk's weight loss drug Wegovy slashes risk of serious heart events

CNBC • 11/11/23

Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.

Market Watch • 11/10/23

Wegovy Maker Novo Nordisk Pumps $6 Billion To Boost Production As Obesity Drug Rival Zepbound Is Approved

Forbes • 11/10/23

Novo Nordisk, maker of Ozempic and Wegovy, to invest more than $6 billion to expand production

Market Watch • 11/10/23